BACKGROUND AND PURPOSE: CV following aneurysmal SAH is a significant cause of morbidity and mortality. We review our experiences using PTA and IA verapamil infusion for treating medically refractory cases.
C
V following aneurysmal SAH is a leading cause of morbidity and mortality. 1 Intracranial arterial narrowing and impaired cerebral autoregulation can reduce CBF and cause signs of ischemia as early as 72 hours after aneurysm rupture. [2] [3] [4] [5] Noninvasive medical measures to restore CBF are centered on hyperdynamic therapy, which consists of hypertension, hemodilution, and hypervolemia. 6 However, not all patients can tolerate this treatment, and of those who can, Յ20% still develop CV severe enough to cause infarction and/or death. 7, 8 In these medically refractory cases, endovascular treatment provides an invasive therapeutic option. PTA and IA vasodilator infusion are the current modes of treatment. PTA is effective at expanding the luminal caliber, increasing CBF, and improving neurologic function. [9] [10] [11] [12] [13] However, PTA is limited to CV of the proximal large arteries at the base of the brain and has a reported 2%-5% risk of stroke or death. 14 The data surrounding IA vasodilator infusions are less established. Most experience is with papaverine, which has questionable clinical benefits and has significant side effects. 11, 15, 16 As a result, a shift toward calcium channel antagonists has emerged, with early reports showing angiographic response and clinical improvement with a better safety profile than either PTA or papaverine. 17 At UCSF Medical Center, we use PTA and IA verapamil to treat medically refractory CV. Verapamil was chosen over other calcium channel antagonists because it has a long and safe history for treating coronary vasospasm. 18 Our philosophy for treating medically refractory CV is that angiographically proved CV in a patient with ischemic symptoms warrants endovascular intervention. The purpose of this study was to describe our recent experience using endovascular treatments in this patient population.
Materials and Methods

Patients
A retrospective chart review was conducted from July 2003 to January 2008 of all patients with aneurysmal SAH confirmed by nonenhanced head CT or lumbar puncture admitted to the UCSF Medical Center within 72 hours of symptom onset. Patients who presented to or were transferred to UCSF Medical Center Ͼ72 hours into their course of SAH were excluded from this analysis due to presumed greater het-erogeneity of initial care at outside institutions or lack of care when presenting in a delayed fashion. We extracted the following data: patient age and sex, date of symptom onset, HH grade, 19 Fisher scale, 20 aneurysm location and treatment, distribution and severity of the CV, endovascular treatments and complications, and mRS 21 at the latest follow-up. Approval from the institutional review board was obtained.
Initial Patient Management
All patients were admitted to the neurointensive care unit where they received standard SAH management, including oral nimodipine. A conventional 4-vessel DSA was performed to confirm the presence of an aneurysm and to serve as a baseline. Ruptured aneurysms were secured by surgical clips or endovascular coil exclusion. Frequent neurologic examinations and, when available, TCD sonograms were obtained. Patients were placed on hyperdynamic therapy when they developed new neurologic deficits not explained by other causes (rebleeding, hydrocephalus, seizures, infection, or metabolic disturbances). Patients with rising TCD velocities due to vasospasm were also placed on hyperdynamic therapy even if they had not yet developed focal neurologic deficits. The target systolic blood pressure for hyperdynamic therapy was 160 mm Hg in normotensive patients and 180 mm Hg in hypertensive patients. Those with persistent, worsening, or recurrent neurologic deficits or increasing TCD velocities and Lindegaard ratios after 12-24 hours or complications limiting hyperdynamic therapy, such as congestive heart failure or cerebral ischemia, were considered medically refractory and were taken to the neuroangiography suite for further evaluation.
Endovascular Treatment
An initial DSA was performed to confirm the presence of angiographic CV and determine its distribution. The supraclinoid ICA, M1 MCA, A1 ACA, intracranial vertebral artery, basilar artery, and P1 PCA were considered "proximal" vessels. Those beyond the above classification (eg, M2 MCA, A2 ACA, P2 PCA) were considered "distal" vessels in the sense that catheterization and PTA of these smaller vessels would likely have a higher than acceptable risk of vessel rupture, given their small size at baseline. The severity of CV was determined by visually assessing the luminal narrowing compared with adjacent vessels and with the baseline DSA by experienced interventional neuroradiology attending physicians (C.F.D., V.V.H., R.T.H.). Mild CV was Ͻ30%, moderate CV was between 30% and 60%, and severe CV was Ͼ60% luminal narrowing. Patients were treated with PTA and/or IA verapamil at the discretion of the interventional neuroradiology attending physician. Generally, severe proximal CV was treated with PTA, and distal CV was treated with IA verapamil.
PTA was performed as previously described. 12 Patients undergoing PTA were systemically anticoagulated by using intravenous heparin in a weight-based bolus dose (typically 4000 -6000 U total) with a goal of doubling baseline activated clotting time. A guiding catheter was placed on heparinized saline drip in either the cervical ICA or cervical vertebral artery. Next, a low-compliance-tip occlusion balloon microcatheter (Sentry-10, Boston Scientific, Fremont, California or HyperGlide, ev3, Irvine, California) was navigated over a compatible 0.010-inch microwire to the most distal aspect of the spastic vessel segment to be treated (ie, the smallest spastic arterial branch farthest from the femoral access site). Brief (Ͻ30 seconds) and repeated inflation-deflation cycles (Յ5) with iodinated contrast material were performed to achieve at least 70% of the expected baseline vascular luminal diameter. The PTA catheter was then withdrawn proximally by 50% of the balloon length (eg, 5-mm pull back for a 10-mmlength balloon), and this process was repeated as necessary to cover all the spastic arterial segments. Heparinization was reversed with protamine at the conclusion of the procedure. IA verapamil infusion was performed by positioning the diagnostic catheter (5F UCSF2; Codman Neurovascular, Miami Lakes, Florida) in the proximal cervical ICA, the distal CCA (if vascular tortuosity or atherosclerotic stenosis precluded safe ICA catheterization), or the cervical vertebral artery proximal to the spastic vessel segment (eg, the ipsilateral ICA for treatment of distal vasospasm in the MCA or ACA). Verapamil was diluted in normal saline to a final concentration of 0.5 mg/mL and infused at a rate of 0.5 mg per minute. For the few cases of isolated or particularly severe ACA or MCA vasospasm, a microcatheter (Prowler-14 LP ES, Codman Neurovascular or Excelsior SL-10, Boston Scientific) over a compatible 0.014-inch guidewire (Transend EX Platinum, Boston Scientific) was navigated to the A1 ACA, A2 ACA, or M1 MCA. Patients undergoing this microcatheterization were systemically heparinized in a manner similar to that in the patients undergoing PTA, with protamine reversal after microcatheter IA verapamil infusion. The dose of verapamil infused in each patient was determined by the catheter position and CV severity. Higher doses of verapamil were used in the less selective catheterizations (eg, CCA catheter position versus ICA catheter position) and in more severe CV.
Repeat DSA was performed to assess treatment response and complications in all patients immediately following PTA and either immediately or Յ30 minutes following IA verapamil infusion. Although the vasodilatory effects of PTA are seen immediately, in our experience, the full vasodilatory effects of verapamil are not realized for 30 minutes to an hour following infusion, which has been corroborated in animal studies. 22 We generally chose to minimize procedural time, thereby procedural risk, as opposed to waiting 30 minutes after verapamil infusion to angiographically confirm the full vasodilatory effect. In particularly severe cases of CV, however, control angiograms were obtained after a 30-minute delay. All complications were recorded.
Patient Outcome
Patient outcome was measured by using the mRS at time of the last follow-up by a stroke neurologist, neurosurgeon, or interventional neuroradiologist. Outcome was considered good when the patient could perform the activities of daily living independently (mRS, Յ2), while outcome was considered poor when the patient required assistance (mRS, 3-5). Causes of patient death (mRS, 6) were recorded.
Statistical Analysis
Data are presented by using descriptive statistics. For parametric data, we provide mean Ϯ SD. For nonparametric data, median and ranges are provided. A Kruskal-Wallis 1-way analysis of variance was used to determine whether there was a significant difference in the dose of verapamil infused, depending on CV severity. Post hoc testing was performed by using the Mann-Whitney U test for pair-wise comparisons. A 2 test was used to determine whether there was a significant difference in stratified patient outcomes. Significance was set at a P value Ͻ .05. 
Results
Patient Characteristics
Endovascular Treatment
The median time between symptom onset and endovascular treatment was 5 days (range, 2-13 days). The distribution and severity of medically refractory CV at the start of each treatment session is shown in Table 1 . In total, 346 endovascular treatments were performed consisting of 1 case (0.3%) of PTA, 286 cases (83%) of IA verapamil infusion, and 59 cases (17%) of combined PTA and verapamil infusion. PTA was performed on 151 vessel segments as shown in Table 2 . All vessels were successfully dilated following PTA on posttreatment DSA. IA verapamil was infused in 720 vessel segments at a median dose as shown in Table 3 . The dose of IA verapamil infused into the ICAs and vertebral arteries increased with worsening CV severity (P Ͻ .05). Supra-and subselective infusions (ie, CCA, M1 MCA, and A1-A2 ACA) were excluded from this analysis for comparison purposes. The median total dose of verapamil infused per treatment session was 20.0 mg (range, 3.0 -55.0 mg). Of the 189 patients, 87 (46%) underwent a single treatment session, 63 (33%) underwent 2 treatment sessions, 27 patients (14%) underwent 3 treatment sessions, 8 (4%) underwent 4 treatment sessions, and 4 (2%) underwent 5 treatment sessions. Of the 346 treatment sessions performed, 157 (45%) were repeated for persistent, worsening, or recurrent neurologic deficits. Repeat treatments were performed in 147 patients (51%) treated with verapamil alone, 10 (17%) treated with PTA and verapamil, and in no patients treated with PTA alone. The mean interval between treatments was 3 Ϯ 2 days. On repeat DSA, the distribution and severity of CV improved in 52 cases, was unchanged in 28 cases, and worsened in 77 cases. Of note, only a single vessel required repeat PTA for recurrent CV.
Treatment-Related Complications
There were 6 treatment-related complications in 189 patients (3.2% per patient rate) during 349 treatment sessions (1.7% per procedure rate). These occurred in different patients during separate treatments and included 3 vessel dissections, 1 vessel perforation, 1 intractable rise in ICP, and 1 thromboembolic event. None of these complications resulted in patient death; 2 intraprocedural complications (1.1% per patient rate, 0.6% per procedure rate) resulted in clinical worsening. A single case of intractable ICP elevation occurred after the infusion of 12.5 mg of verapamil into each ICA. Opening the extraventricular drain failed to relieve pressure, and the patient was taken for emergent decompressive craniectomy. Thromboembolism occurred in 1 case of PTA and was treated with intravenous abciximab infusion. The patient developed unilateral upper extremity weakness with a new infarct on CT. On 6-month follow-up examination, the patient had regained full strength in the extremity. Asymptomatic vascular dissections occurred in 2 cervical vertebral arteries and 1 cervical ICA as a result of catheterization. Stents were deployed in the vertebral arteries, and PTA was performed in the cervical ICA to restore flow. Asymptomatic intracranial arterial perforation occurred when a guidewire punctured the supraclinoid ICA. This was treated by reversal of heparinization and temporary balloon occlusion until resolution of contrast extravasation. There were no hemodynamic complications associated with verapamil infusion. 
Clinical Outcome
Longitudinal outcome data (Fig 2) were available for 153 patients (81%) after a median of 180 days (range, 32-1637 days) following discharge. Thirty-six patients were lost to follow-up, and their discharge mRS score was used. In our study population, 115 patients (61%) had a good outcome (mRS Յ 2), 55 patients (29%) had a poor outcome (mRS 3-5), and 19 patients (10%) died in the hospital. Patients were further stratified into 2 groups on the basis of their HH score. Of 137 patients (72%) with a good clinical presentation (HH scores, 1-3), 98 (72%) had a good outcome, 34 (25%) had a poor outcome, and 5 (4%) died in the hospital. Of 52 patients (28%) with a poor clinical presentation (HH scores, 4 and 5), 17 (33%) had a good outcome, 21 (40%) had a poor outcome, and 14 (27%) died in the hospital. There was a significant difference in all clinical outcome measures between the stratified groups ( 2 , P Ͻ .001). Of the 19 patients who died, 16 died from causes related to their aneurysm rupture, while 3 died from other medical complications, including pneumonia, acute respiratory distress syndrome, and sepsis.
Discussion
This study examines our recent experience using PTA and IA verapamil to treat patients with aneurysmal SAH with medically refractory CV. We treated 189 patients during 349 treatment sessions, consisting of a single angioplasty, 286 IA verapamil infusions, and 59 combined therapies. In total, 151 vessel segments underwent PTA and 720 vessel segments were infused with verapamil. The procedural complication rate was 1.7% per procedure and 3.2% per patient. The clinically significant procedural complication rate was 0.6% per procedure and 1.1% per patient. Ultimately, 61% of patients had a good clinical outcome. To our knowledge, this constitutes the largest series of patients having undergone endovascular treatment for CV to date.
The goal of CV management is to prevent cerebral ischemia. Cerebral ischemia is likely a multifactorial process, but it is recognized that intracranial arterial luminal narrowing significantly reduces CBF. 3, [23] [24] [25] This relationship is explained by the Poiseuille equation, which states that flow is directly proportional to the pressure gradient and radius to the fourth power and inversely proportional to the fluid viscosity and vessel length. This forms the basis for a hyperdynamic therapy that tries to optimize the pressure gradient and fluid viscosity to improve CBF. 26 However, there is a limit to how much these parameters can be modified before complications such as pulmonary edema, dilutional hyponatremia, and myocardial infarction occur. 26, 27 PTA and IA verapamil infusion are invasive options for restoring luminal caliber by mechanical or pharmaceutical means, respectively. The choice of endovascular treatment is dictated by the distribution and severity of CV. PTA is limited to vessels that can safely accommodate the balloon microcatheter: the major cerebral arteries at the base of the brain and their most proximal branches. 14 We further restricted the use of PTA to those vessels demonstrating severe CV. Because PTA has previously been reported to have a 2%-5% risk of stroke and death, 14 we believe the risk-to-benefit ratio is minimized when only severe disease is treated. However, the performance characteristics of low-compliance balloon microcatheters have improved, and our own level of experience has increased significantly during the past 2 decades. Thus, our current complication rate from PTA (1.7%, see the discussion below) is lower than that in an earlier series from our institution (7.1%). 12 In our current series, PTA was performed in 60 patients (67%) of 90 in whom there was severe proximal or severe proximal and distal CV (Table 1 ). This rate implies that 33% of cases were either inaccessible or unfavorable for treatment by PTA. Examples include CV of the A1 segment, which is difficult to cannulate with a balloon microcatheter 9, 10, 12, 28, 29 or which may be hypoplastic at baseline and thus not safe to balloon dilate. If no prior angiogram existed demonstrating that the A1 segment was not hypoplastic at baseline, then PTA of the A1 segment was avoided. PTA of a vasospasm involving the vessel segment immediately adjacent to an aneurysm, which is associated with vessel rupture or surgical clip displacement, 30 was also considered to be contraindicated.
In cases in which PTA could not be performed, we infused IA verapamil. Verapamil has been used for about 10 years to treat CV, but optimal dosing remains in question. [31] [32] [33] [34] [35] We infused 2.0 -30.0 mg per vessel segment. In our experience, these doses improved the luminal caliber in most cases; however, this finding cannot be confirmed on this retrospective study because delayed posttreatment DSA was not routinely performed in all patients. The efficacy of verapamil in improving the luminal caliber has been shown in earlier series: Feng et al 32 found a 44% increase in vessel diameter following an average and maximum dose of 3 and 8 mg, respectively. Keuskamp et al 33 showed a significant increase in vessel diameter in 10 of 12 patients who were given Ն20 mg per vessel segment. Although Mazumdar et al 34 failed to show a significant increase in vessel diameter after 2.5-10.0 mg of verapamil, there was a trend to vasodilation in the most spastic vessels.
In our series, there was a direct correlation between the amount of verapamil infused and the severity of CV (Fig 3) . Although this conclusion is intuitive and has been reported anecdotally in other studies, 32 several confounding factors need to be considered. First, because CV severity was determined by visual inspection, there can be miscategorization, particularly in borderline cases. Second, even though our findings are statistically significant, they may not be clinically significant, given the wide overlap in doses between groups. Third, treatment bias is likely present because the amount of verapamil infused could be determined by operator experience rather than angiographic response. During the study period, all participating interventional neuroradiology attending physicians had 15-20 years of experience treating patients with SAH and CV. Finally, verapamil infusion is known to have an effect on spastic prearteriolar vessels, which are below the resolution of DSA. 22 Functional measures such as CBF may thus be better end points for determining optimal verapamil dosing. 4, 24, 36 There are limited data related to the durability of endovascular treatments. In our study, repeat treatments were performed in 102 patients (54%); 17% of cases treated with PTA and IA verapamil and 51% of cases treated with IA verapamil alone required repeat treatments. PTA had excellent durability in our series, with only a single vessel segment (2%) requiring repeat PTA. This is in keeping with other series that have shown that vessel segments treated with angioplasty rarely restenose to the point of warranting further therapy. 10, 37 The durability of PTA has been explained by the ultrastructural changes that occur within the media of the mechanically dilated vessel wall. 38, 39 The length of therapeutic effect of IA verapamil in CV is not known. Although the biologic half-life of intravenous verapamil is 110 minutes, 40 the persistence of its vasodilatory effect on the cerebral arteries is poorly understood. The coronary artery literature is not particularly instructive because coronary vasospasm tends to be much shorter lived (minutes) than CV (days to weeks). 18 Whereas coronary vasospasm will resolve on its own in less than the half-life of verapamil, CV often persists well beyond the expected half-life of verapamil in the cerebral circulation. Thus, IA verapamil may have to be re-administered multiple times during a course of protracted CV to maintain CBF and prevent ischemia. The optimal time interval between IA verapamil infusions is not known, though most patients treated repeatedly with IA verapamil at our institution had a mean of 3 days in between. Prolonged IA verapamil infusion (for Յ20.5 hours) with in-dwelling catheters has recently been described and provides a novel mode of administration. 31 Our recent experience demonstrates the safety of endovascular vasospasm therapy by using PTA and/or IA verapamil infusion. There were no treatment-related deaths, and of the 6 procedural complications, only 2 resulted in patient clinical deterioration. Distal embolization following PTA is a recognized complication and, in our patient, resulted in short-term disability with later full recovery. However, to our knowledge, intractable ICP elevation following IA verapamil has not been previously reported. Albanese et al 31 described a single patient with transient ICP elevation during prolonged IA verapamil infusion that resolved on treatment cessation. Other studies have shown that IA verapamil has a negligible effect on ICP at similar or higher doses than that used to treat our patient. [32] [33] [34] Although this case may represent refractory cerebral edema in a critically ill patient with SAH, given its temporal relationship to IA verapamil infusion, vigilant ICP monitoring is warranted.
Although endovascular vasospasm therapies are safe, their efficacy remains poorly characterized. Both PTA and IA verapamil have been shown to improve neurologic status in the short term, but their long-term benefits remain inconclusive. In our series, 61% of patients had a good outcome, 29% had a poor outcome, and 10% died. Historically, mortality rates after SAH have been reported to be as high as 67% with up to a third requiring lifelong care. 41 In the modern era, mortality and morbidity have steadily decreased and the ISAT reported the following outcomes after 1 year: 72% good, 18% poor, and 9% dead. 42 However, the patient population of that trial differs significantly from the patient population in the current series. Specifically, ISAT included many patients who did not have medically refractory CV, thus constituting a less morbid cohort than that presented our series. Thus, the outcomes in our tertiary care referral center may be similar, if not better, than other published clinical trials.
Ultimately, safety without efficacy is meaningless, and in the absence of efficacy, any patient risk is unwarranted. To our knowledge, there are no randomized studies of the effect of endovascular treatment for CV on outcomes. Small uncontrolled studies report a wide range of clinical improvement: 10%-80%. 43 More rigorously controlled trials of CV therapies are, therefore, warranted. Given the current paradigm that CV causes ischemia and disabling infarction in Յ20% of patients with SAH, comparison of PTA and/or IA verapamil or other vasodilators with a pure placebo (ie, sham endovascular treatment) would be unethical. Trials comparing IA vasodilators of differing pharmacologic actions, such as verapamil and milrinone, would be an appropriate next step in the further elucidation of safe and efficacious prevention of CV-induced cerebral infarction.
Conclusions
In summary, endovascular treatments are an integral part of managing patients with medically refractory CV. In our experience, endovascular vasospasm therapy is safe, with a low complication rate both for PTA and IA verapamil infusion. These data will serve as an impetus for further efficacy studies aimed at reducing the morbidity and mortality of patients with aneurysmal SAH.
